Zack's Investment Research Reports on OPTIMIZERx: Initiates "Outperform" Rating
28 September 2011 - 2:00PM
Marketwired
OPTIMIZERx Corporation (OTCBB: OPRX) today announced Zack's
Investment Research coverage of the company. The following
summarizes the Outlook and entire report on OPTIMIZERx can be read
in its entirety by clicking here.
Zack's Investment Outlook on OPTIMIZERx (OPRX):
"OPTIMIZERx's SampleMD software, which was integrated into
Allscripts' e-prescription system in late 2010, affords prescribers
seamless access to a universe of sample vouchers and prescription
co-pay coupons. Allscripts, with ~100k prescribers using its
system, is the largest e-prescriber provider. SampleMD provides
pharmaceutical companies a novel way to promote their drugs. OPRX
receives revenue from manufacturers for every coupon that is
printed or redeemed.
"With the launch still in its infancy, revenue has been modest
but is expected to ramp as the user base expands and utilization
grows. Business model is super scalable. OPRX runs very lean and
should have sufficient cash/financing until reaching positive cash
flow.
"We think OPRX could hit profitability by 2012. We are
initiating with a $5.00 price target and Outperform rating."
About OPTIMIZERx Corp.
OPTIMIZERx Corp. provides unique consumer and physician
platforms to help patients better afford and comply with their
medicines and healthcare products, while offering pharmaceutical
and healthcare companies effective ways to expand patient
awareness, access and adherence to their brands. For more
information, please go to www.optimizerxcorp.com.
'SAFE HARBOR'
This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as
amended and such section 21E of the Securities Act of 1934,
amended. These forward-looking statements should not be used to
make an investment decision. The words 'estimate,' 'possible' and
'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material risks.
Contact: David Harrell Email Contact 248.651.6568
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024